XML 65 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Common Share (Tables)
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Earnings Per Share
The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):
Year Ended December 31,
202320222021
Numerator
Income (loss) from continuing operations$334,757 $513,540 $137,728 
Noncontrolling interests’ share in continuing operations(28,748)(15,975)(17,851)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.306,009 497,565 119,877 
Less: Participating securities’ share in continuing operations(1,725)(2,657)(3,269)
Income (loss) from continuing operations applicable to common shares304,284 494,908 116,608 
Income (loss) from discontinued operations— 2,884 388,202 
Noncontrolling interests’ share in discontinued operations— — (2,539)
Net income (loss) applicable to common shares - basic and diluted$304,284 $497,792 $502,271 
Denominator
Basic weighted average shares outstanding547,006 538,809 538,930 
Dilutive potential common shares - equity awards(1)
269 338 310 
Dilutive potential common shares - forward equity agreements(2)
— — 
Diluted weighted average common shares547,275 539,147 539,241 
Basic earnings (loss) per common share
Continuing operations$0.56 $0.92 $0.22 
Discontinued operations— 0.00 0.71 
Net income (loss) applicable to common shares$0.56 $0.92 $0.93 
Diluted earnings (loss) per common share
Continuing operations$0.56 $0.92 $0.22 
Discontinued operations— 0.00 0.71 
Net income (loss) applicable to common shares$0.56 $0.92 $0.93 
_______________________________________
(1)For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).
(2)For the year ended December 31, 2023, forward equity sales agreements had no dilutive impact as no shares were outstanding under ATM forward contracts during the year. For the year ended December 31, 2022, all 9.1 million shares that were settled during the year then ended were anti-dilutive. For the year ended December 31, 2021, represents the dilutive impact of 9.1 million shares that were not settled during the year then ended.